• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Novo Nordisk’s once-weekly Type II diabetes med approved in Europe

February 9, 2018 By Sarah Faulkner

Novo NordiskThe European Commission has approved Novo Nordisk‘s (NYSE:NVO) once-weekly semaglutide drug, Ozempic, as a treatment for adults with Type II diabetes.

The GLP-1 analogue’s label in Europe recommends that the drug is given when metformin is contraindicated or not tolerated, Novo Nordisk reported today.

The E.U. agency approved Ozempic for use in a multi-dose pre-filled pen, but Novo Nordisk said it plans to seek approval for an updated Ozempic pen device. Following the approval of the updated pen, Ozempic is slated to launch in the second half of 2018.

“We are very excited about the approval of Ozempic in the E.U., as we believe it has the potential to set a new standard for the treatment of Type II diabetes,” Mads Krogsgaard Thomsen, Novo Nordisk’s EVP & chief science officer, said in prepared remarks. “Type II diabetes is a complex disease and the strong clinical profile of Ozempic provides a much-needed treatment option for people looking for efficacious solutions to manage their disease.”

Earlier this year, Health Canada approved Ozempic as an adjunct to diet and exercise for adults with Type II diabetes. The drug also won FDA approval in the U.S. in December.

In clinical trials, people who used Ozempic experienced statistically significant and sustained blood sugar control compared to people using medicines like once-daily insulin glargine or extended-release formulations of exenatide.

In one 40-week trial of 1,200 patients, Ozempic succeeded in lowering glucose levels in patients with Type II diabetes and demonstrated statistically significant results compared to Eli Lilly‘s (NYSE:LLY) dulaglutide compound.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: Novo Nordisk

IN CASE YOU MISSED IT

  • Medtronic to separate Diabetes business unit
  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS